Lung imaging software developer Vida Diagnostics has raised $11 million to help with the commercialization of its artificial intelligence (AI)-powered lung analysis software, LungPrint.
First Analysis Corporation led the funding round, with equity participation from Blue Heron Capital and UnityPoint Health Ventures. The company also received support from NextLevel Ventures, Chartline Capital Partners, Rural Vitality Fund, Rittenhouse Ventures, Iowa First Capital Fund, and the Angels' Forum.